• Profile

The Crohn disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn disease (CDED-AD): An open-label, pilot, randomised trial

The Lancet: Gastroenterology & Hepatology Nov 07, 2021

Yanai H, Levine A, Hirsch A, et al. - In adults suffering from mild-to-moderate biologic naïve Crohn disease, CDED (Crohn disease exclusion diet) with or without partial enteral nutrition showed effectiveness for induction as well as maintenance of remission and might result in endoscopic remission. According to findings, CDED could be employed for mild-to-moderate active Crohn's disease.

  • An open-label, pilot randomized trial of adults with Crohn's disease who were randomly assigned (n=44) (1:1) to CDED plus partial enteral nutrition or CDED alone for 24 weeks.

  • At week 6, clinical remission was achieved by 68% of patients in the CDED plus partial enteral nutrition group and by 57% of patients in the CDED group.

  • Among the 25 patients in remission at week 6, 80% (n=20) were in sustained remission at week 24 (12 in the CDED plus partial enteral nutrition group and 8 in the CDED alone group).

  • At week 24, 35% were in endoscopic remission (n=14/40) (8 in the CDED plus partial enteral nutrition group and 6 in the CDED alone group).

  • In both groups, no serious adverse events or treatment-related adverse events occurred.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen